Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Roger Sidhu"'
Autor:
Omid Hamid, Siqing Fu, Manish Sharma, Anna Spreafico, Kyriakos P Papadopoulos, Erika Hamilton, Alexander Spira, Quincy Chu, Brigette Ma, Emily Roberts-Thomson, Dih-Yih Chen, Judy S Wang, Scott A Laurie, Mark R Bray, Roger Sidhu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b9d18b36b4844c1ab02ca1daf51708cf
Autor:
Harriet Feilotter, Larry D. Greller, Roland Somogyi, Karen Harrison, Hong Guo, Roger Sidhu, Patricia Farmer, Cheryl Foster, Tara Baetz, David LeBrun
Purpose: Follicular lymphoma is a common lymphoma of adults. Although its course is often indolent, a substantial proportion of patients have a poor prognosis, often due to rapid progression or transformation to a more aggressive lymphoma. Currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7af071522ef66cc4dcf9194e554ae224
https://doi.org/10.1158/1078-0432.c.6518128
https://doi.org/10.1158/1078-0432.c.6518128
Autor:
Scott D. Patterson, Roger Sidhu, Andre S. Jung, Jan-Henrik Terwey, Reija Koukakis, Hua Yu, Pei He, Eric Van Cutsem, Laslo Roman, Tudor E. Ciuleanu, Gregory Wilson, Andrew H. Strickland, Cornelis J.A. Punt, Florian Lordick, Emily Chan, Thierry André, Yevhen Hotko, Michel Ducreux, Alberto F. Sobrero, Andrés Cervantes, Timothy J. Price, Kelly S. Oliner, Marc Peeters
Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::236fc56665240edab4fb993d5fdfdc8c
https://doi.org/10.1158/1078-0432.c.6524502
https://doi.org/10.1158/1078-0432.c.6524502
PDF file - 73 KB, Correlation Between Overall Survival Hazard Ratios and Response Rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7814395005d14590b31ba859480a742e
https://doi.org/10.1158/1078-0432.22449812
https://doi.org/10.1158/1078-0432.22449812
Pooled analyses of chemotherapy trials in metastatic colorectal cancer (mCRC) have suggested that progression-free survival (PFS) is a surrogate endpoint for overall survival (OS). However, this has not been evaluated under current standard-of-care r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::527f03566bc190b07f58e924f439d3a5
https://doi.org/10.1158/1078-0432.c.6521759
https://doi.org/10.1158/1078-0432.c.6521759
PDF file - 65 KB, Overall survival (OS) hazard ratios (HR) versus progression free survival (PFS) HRs - Unweighted Analysis. (A) All selected trials.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e68222200d7ffe802ee5a23f1839249
https://doi.org/10.1158/1078-0432.22449821.v1
https://doi.org/10.1158/1078-0432.22449821.v1
Autor:
Scott D. Patterson, Roger Sidhu, Andre S. Jung, Jan-Henrik Terwey, Reija Koukakis, Hua Yu, Pei He, Eric Van Cutsem, Laslo Roman, Tudor E. Ciuleanu, Gregory Wilson, Andrew H. Strickland, Cornelis J.A. Punt, Florian Lordick, Emily Chan, Thierry André, Yevhen Hotko, Michel Ducreux, Alberto F. Sobrero, Andrés Cervantes, Timothy J. Price, Kelly S. Oliner, Marc Peeters
Contains: Table S1. RAS and BRAF Mutation Status Table S2. Objective Response Rate in Patients with Mutated RAS Table S3. Depth of Response and Early Tumor Response in Wild-type KRAS Exon 2 Patients Figure S1. Disposition of patients in the study and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a270e11af1fd12d264083118e64d68d8
https://doi.org/10.1158/1078-0432.22460478
https://doi.org/10.1158/1078-0432.22460478
Autor:
Harriet Feilotter, Larry D. Greller, Roland Somogyi, Karen Harrison, Hong Guo, Roger Sidhu, Patricia Farmer, Cheryl Foster, Tara Baetz, David LeBrun
Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2398b963789b2e28ed18f7b65eeb1ebf
https://doi.org/10.1158/1078-0432.22440868.v1
https://doi.org/10.1158/1078-0432.22440868.v1
Autor:
Alireza Moslemian, Ryan Willing, Alan Getgood, Roger Sidhu, Philip P. Roessler, Ryan M. Degen, Ryan Wood
Publikováno v:
Bone and Joint Institute
© 2020 Elsevier Ltd Clinical outcomes following posterior cruciate ligament (PCL) reconstruction are often suboptimal. A better understanding of the biomechanical contributions of the PCL to knee stability under physiologic, clinically-relevant load